D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours

['lizbeth]

ClinicalTrials.gov Identifier:
NCT01851265

http://clinicaltrials.gov/ct2/show/N...o_unk=Y&rank=4

This is a 2 part study for patients with solid tumours. The purpose of Part A is to measure the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after eating 3 different breakfasts (high calorie, regular and none). In Part B Patients can take olaparib capsules daily and study assessments will be recorded for 6 months (minimum). Treatment can continue for as long as the patient is benefitting. Throughout the study patients will be monitored for any side effects.